Legal & Financial Issues
NCP Flanders guides and supports you with all legal and financial issues during the complete life cycle of Horizon Europe and Digital Europe
News updates & event announcements
NCP Flanders provides news updates and events event announcement on legal and financial aspects for both Horizon Europe and the Digital Europe programme. You can find the info here:
Reference documents
All available reference documents for Horizon Europe and Digital Europe can be found on the Funding and Tender Portal. Herewith an overview of different types of reference documents that are pivotal for applicants/beneficiaries in the programmes:
|
|
Horizon Europe |
Digital Europe |
| Model Grant Agreement |
||
|
Annotated Model Grant Agreement – user guide, explaining the grant agreement |
Find it here |
Find it here |
|
Programme Guide - details on structure, budget, political priorities, proposal preparation |
Find it here |
Not applicable |
|
Indicative Audit Programme |
Foreseen 2024 |
Not applicable |
Online manual
In the Online Manual extensive details can be found regarding the application process as well as the Evaluation and Grant Signature Procedure and Grant Management.
Infosheets on Legal & Financial issues
NCP Flanders’ Infosheets offer a deep dive into specific issues and answer to frequently asked questions. It is worthwhile having a look as several of our Infosheets focus on legal and financial aspects.
Testimonial
BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
